These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19376640)

  • 1. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.
    Gouas D; Shi H; Hainaut P
    Cancer Lett; 2009 Dec; 286(1):29-37. PubMed ID: 19376640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.
    Szymañska K; Chen JG; Cui Y; Gong YY; Turner PC; Villar S; Wild CP; Parkin DM; Hainaut P
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1638-43. PubMed ID: 19366907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.
    Gouas DA; Shi H; Hautefeuille AH; Ortiz-Cuaran SL; Legros PC; Szymanska KJ; Galy O; Egevad LA; Abedi-Ardekani B; Wiman KG; Hantz O; Caron de Fromentel C; Chemin IA; Hainaut PL
    Carcinogenesis; 2010 Aug; 31(8):1475-82. PubMed ID: 20538734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies.
    Stern MC; Umbach DM; Yu MC; London SJ; Zhang ZQ; Taylor JA
    Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):617-25. PubMed ID: 11401911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
    Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
    Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
    Kirk GD; Lesi OA; Mendy M; Szymañska K; Whittle H; Goedert JJ; Hainaut P; Montesano R
    Oncogene; 2005 Sep; 24(38):5858-67. PubMed ID: 16007211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of TP53 codon 249 mutations in young Guinean children with high aflatoxin exposure.
    Turner PC; Sylla A; Kuang SY; Marchant CL; Diallo MS; Hall AJ; Groopman JD; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):2053-5. PubMed ID: 16103461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 and hepatocellular carcinoma.
    Puisieux A; Ozturk M
    Pathol Biol (Paris); 1997 Dec; 45(10):864-70. PubMed ID: 9769950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characteristics of high frequency 249 codon mutation of p53 gene in hepatocellular carcinoma in prevalent area of China].
    Ming L; Yuan B; Thorgeirsson SS
    Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):122-4. PubMed ID: 11776852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
    Hosny G; Farahat N; Tayel H; Hainaut P
    Cancer Lett; 2008 Jun; 264(2):201-8. PubMed ID: 18313840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients.
    Jackson PE; Kuang SY; Wang JB; Strickland PT; Muñoz A; Kensler TW; Qian GS; Groopman JD
    Carcinogenesis; 2003 Oct; 24(10):1657-63. PubMed ID: 12869416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 codon 249 mutation in hepatocellular carcinomas from Nigeria.
    Ndububa DA; Yakicier CM; Ojo OS; Adeodu OO; Rotimi O; Ogunbiyi O; Ozturk M
    Afr J Med Med Sci; 2001; 30(1-2):125-7. PubMed ID: 14510167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic stability prevails in North-African hepatocellular carcinomas.
    Pineau P; Ezzikouri S; Marchio A; Benazzouz M; Cordina E; Afifi R; Elkihal L; Khalfallah MT; Mestiri H; Tebbal S; Berkane S; Debzi N; Triki H; Dejean A; Iguer F; Bahri O; Essaid El Feydi AE; Benjelloun S
    Dig Liver Dis; 2007 Jul; 39(7):671-7. PubMed ID: 17531558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis.
    Villar S; Ortiz-Cuaran S; Abedi-Ardekani B; Gouas D; Nogueira da Costa A; Plymoth A; Khuhaprema T; Kalalak A; Sangrajrang S; Friesen MD; Groopman JD; Hainaut P
    PLoS One; 2012; 7(6):e37707. PubMed ID: 22675488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 and liver carcinogenesis.
    Staib F; Hussain SP; Hofseth LJ; Wang XW; Harris CC
    Hum Mutat; 2003 Mar; 21(3):201-16. PubMed ID: 12619106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention.
    Wild CP; Montesano R
    Cancer Lett; 2009 Dec; 286(1):22-8. PubMed ID: 19345001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure biomarkers in chemoprevention studies of liver cancer.
    Wild CP; Turner PC
    IARC Sci Publ; 2001; 154():215-22. PubMed ID: 11220661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutation in hepatocellular carcinoma after aflatoxin exposure.
    Ozturk M
    Lancet; 1991 Nov; 338(8779):1356-9. PubMed ID: 1682737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of electrospray ionization mass spectrometry detection of codon 249 mutations in the p53 gene compared with RFLP.
    Qian GS; Kuang SY; He X; Groopman JD; Jackson PE
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1126-9. PubMed ID: 12376521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma.
    Marchio A; Amougou Atsama M; Béré A; Komas NP; Noah Noah D; Atangana PJA; Camengo-Police SM; Njouom R; Bekondi C; Pineau P
    Clin Exp Med; 2018 Aug; 18(3):421-431. PubMed ID: 29749584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.